Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity

Molecular Pharmacology

Volumn 77, Issue 2, 2010, Pages 247-254

  Murray, Iain A ^a   Morales, Jose L ^a   Flaveny, Colin A ^a   DiNatale, Brett C ^a   Chiaro, Chris ^a   Gowdahalli, Krishnegowda ^b   Amin, Shantu ^b   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450 1A1; CYTOKINE; ESTROGEN RECEPTOR; HYDROCARBON; HYDROCARBON RECEPTOR; LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; INFLAMMATION; MODULATION; PRIORITY JOURNAL; TRANSACTIVATION; WILD TYPE;

ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRAZOLES; RECEPTORS, ARYL HYDROCARBON; TETRACHLORODIBENZODIOXIN;

EID: 74549150183     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061788     Document Type: Article

References (31)

1. Beischlag TV, Luis Morales J, Hollingshead BD, and Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18:207-250.
2. Bhat KP and Pezzuto JM (2001) Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 61: 6137-6144.
3. Booth EA, Marchesi M, Knittel AK, Kilbourne EJ, and Lucchesi BR (2007) The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism. J Cardiovasc Pharmacol 49:401-407.
4. Camacho IA, Singh N, Hegde VL, Nagarkatti M, and Nagarkatti PS (2005) Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells. J Immunol 175:90-103.
5. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, and Savouret JF (1999) Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56:784-790.
6. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, et al. (2005) Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci U S A 102:2543-2548.
7. Flaveny CA, Murray IA, Chiaro CR, and Perdew GH (2009) Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol Pharmacol 75:1412-1420.
8. Harnish DC, Liu X, Kenney T, Winneker RC, Chadwick C, Friedrichs GS, and Kilbourne EJ (2006) The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models. J Cardiovasc Pharmacol 47:788-795.
9. Hogaboam JP, Moore AJ, and Lawrence BP (2008) The aryl hydrocarbon receptor affects distinct tissue compartments during ontogeny of the immune system. Toxicol Sci 102:160-170.
10. Kamath AB, Xu H, Nagarkatti PS, and Nagarkatti M (1997) Evidence for the induction of apoptosis in thymocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin in vivo. Toxicol Appl Pharmacol 142:367-377.
11. Keith JC Jr, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, and Harnish DC Arthritis Res Ther 7:R427-R438.
12. Kerkvliet N, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, and Mourich DV (2009) Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunother 1:539-547.
13. Kerkvliet NI (2002) Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol 2:277-291.
14. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, and Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 105:9721-9726.
15. Matthews J and Gustafsson JA (2006) Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 4:e016.
16. Negishi T, Kato Y, Ooneda O, Mimura J, Takada T, Mochizuki H, Yamamoto M, Fujii-Kuriyama Y, and Furusako S (2005) Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J Immunol 175:7348-7356.
17. North CM, Crawford RB, Lu H, and Kaminski NE (2009) Simultaneous in vivo time course and dose response evaluation for TCDD-induced impairment of the LPSstimulated primary IgM response. Toxicol Sci 112:123-132.
18. Patel RD, Murray IA, Flaveny CA, Kusnadi A, and Perdew GH (2009) Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest 89:695-707.
19. Poland A, Glover E, Ebetino FH, and Kende AS (1986) Photoaffinity labeling of the Ah receptor. J Biol Chem 261:6352-6365.
20. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, and Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:65-71.
21. Reichardt HM, Kaestner KH, Wessely O, Gass P, Schmid W, and Schütz G (1998) Analysis of glucocorticoid signalling by gene targeting. J Steroid Biochem Mol Biol 65:111-115.
22. Safe S and McDougal A (2002) Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. Int J Oncol 20:1123-1128.
23. Safe SH (1995) Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol Ther 67:247-281.
24. Sagredo C, Øvrebø S, Haugen A, Fujii-Kuriyama Y, Baera R, Botnen IV, and Mollerup S (2006) Quantitative analysis of benzo[a]pyrene biotransformation and adduct formation in Ahr knockout mice. Toxicol Lett 167:173-182.
25. Schneider D, Manzan MA, Crawford RB, Chen W, and Kaminski NE (2008) 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated impairment of B cell differentiation involves dysregulation of paired box 5 (Pax5) isoform, Pax5a. J Pharmacol Exp Ther 326:463-474.
26. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, and Nagarkatti P (2007) Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72:1508-1521.
27. Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Eckert A, et al. (2004) Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem 47:6435-6438.
28. Stevens EA, Mezrich JD, and Bradfield CA (2009) The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127:299-311.
29. Tian Y, Rabson AB, and Gallo MA (2002) Ah receptor and NF-kappaB interactions: mechanisms and physiological implications. Chem Biol Interact 141: 97-115.
30. Veldhoen M, Hirota K, Christensen J, O'Garra A, and Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-49.
31. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, and Stockinger B (2008) Nature 453:106-109.